David S. Rosenbloom
Known title: SVP and General CounselCIK: 0001924321
Associated companies
Transaction History
| BAX | ▼ Sell | Tax Withholding | 6,620 | $117K | 3/6/2026 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 1,336 | $26K | 3/2/2026 | View on chart |
| BAX | ▲ Buy | Grant | 26,709 | $0 | 2/27/2026 | View on chart |
| BAX | ▲ Buy | Grant | 17,055 | $0 | 2/9/2026 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 5,225 | $114K | 2/9/2026 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 16,548 | $489K | 6/2/2025 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 4,922 | $174K | 3/6/2025 | View on chart |
| BAX | ▲ Buy | Grant | 17,658 | $0 | 3/6/2025 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 1,312 | $46K | 3/3/2025 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 784 | $27K | 6/3/2024 | View on chart |
| BAX | ▲ Buy | Grant | 53,584 | $0 | 3/6/2024 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 1,416 | $58K | 3/1/2024 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 762 | $31K | 6/1/2023 | View on chart |
| BAX | ▲ Buy | Grant | 13,885 | $0 | 3/1/2023 | View on chart |
| BAX | ▲ Buy | Grant | 7,636 | $0 | 6/1/2022 | View on chart |
| BAX | ▲ Buy | Grant | 33,940 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Baxter International publishes inaugural Connected Hospital Report
Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.
Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.